Evidence map›Paper›PMID 31602369›Full record

ArticleLiver cancer2019

Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.

Tim A Labeur, Jeroen L A van Vugt, David W G Ten Cate, R Bart Takkenberg, Jan N M IJzermans, Bas Groot Koerkamp, Robert A de Man, Otto M van Delden, Ferry A L M Eskens, Heinz-Josef Klümpen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Hepatic immune regulation and sex disparities.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tim A LabeurCancer Center Amsterdam, Amsterdam, The Netherlands.
Jeroen L A van VugtDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
David W G Ten CateDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
R Bart TakkenbergDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Jan N M IJzermansDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Robert A de ManDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Otto M van DeldenDepartment of Radiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Ferry A L M EskensDepartment of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Heinz-Josef KlümpenCancer Center Amsterdam, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have suggested body composition as a predictor of sorafenib toxicity and outcome in patients with advanced hepatocellular carcinoma (HCC). Large studies on the impact of body composition parameters in European HCC patients are lacking. Our aim was to validate the prognostic value of body composition parameters in Dutch patients with HCC treated with sorafenib. PATIENTS AND

methodsA retrospective analysis was performed in a cohort of HCC patients treated with sorafenib at two Dutch tertiary referral centers between 2007 and 2016. Body composition (adipose and skeletal muscle tissue) was measured at baseline by computed tomography (CT). Low skeletal muscle mass (SMM) and density were defined using published cut-offs. Body composition parameters were correlated with overall survival (OS), time to progression, response rate, and toxicity.

resultsA total of 278 patients were included, mostly Child-Pugh class A (85%) and Barcelona Clinic Liver Cancer (BCLC) stage C (73%), with a median OS of 9.5 months (95% CI 8.1-11.0). Patients with combined low SMM and low total adipose tissue index (TATI) (

conclusionsIn Dutch HCC patients treated with sorafenib, the combined presence of low SMM and low TATI was associated with impaired survival, independent of known prognostic factors. CT assessment of body composition may provide additional prognostic information prior to sorafenib treatment.

Indexed as

Body compositionHepatocellular carcinomaPrognosisSkeletal muscle massSorafenibTotal adipose tissue area

Identifiers

PMID31602369
PMCPMC6738194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.